CANTATA: A multicentre, phase II randomised controlled trial evaluating cabazitaxel versus docetaxel re-challenge for the treatment of metastatic Castrate Refractory Prostate Cancer, previously treated with docetaxel at inception of primary hormone therapy

Trial Overview and Summary

The CANTATA  trial compares chemotherapy drugs cabazitaxel and docetaxel for prostate cancer that has spread to other parts of the body.  Men taking part have prostate cancer that has started to get worse after previously having had hormone therapy and docetaxel chemotherapy. 
If prostate cancer has spread outside the prostate gland, doctors often treat it with hormone therapy. This can work very well, but at some stage the cancer may no longer respond to the hormone therapy and start to grow again.  In this case chemotherapy with a drug called docetaxel is often offered. If the cancer returns again, docetaxel may again be offered as a ‘re-challenge’.
Alternatively, cabazitaxel is a newer chemotherapy drug that may be used for the re-challenge.
The researchers are comparing cabazitaxel and a docetaxel re-challenge, specifically to see which treatment helps men more and to learn more about the side-effects.

Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible

Chief Investigator: Professor Nicholas James
Sponsor: University of Birmingham
Funders: Educational Grant from SANOFI and endorsed by Cancer Research UK
Disease Site: Prostate cancer
Trial Type: Chemotherapy / Phase II
Status: Follow-up
UKCRN Study ID: (if applicable) 13741
Open to new sites? No
Recruitment start date: 07 March 2013
Recruitment end date 12 January 2016
CRCTU Trial Management Team: Team A
Trial E-mail Address:

Trial Protocol

Please Note:

Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional or refer to CancerHelp website.

Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.

More information